XML 30 R19.htm IDEA: XBRL DOCUMENT v3.26.1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 11 – SEGMENT INFORMATION

 

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly provided to the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company conducted the business through two primary operating segments: NanoVibronix and ENvue. NanoVibronix derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its systems and nasoenteral tubes. Non-allocated administrative and other expenses are reflected in Corporate.

 

The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information presented by operating segment in making operating decisions, allocating resources, and evaluating financial performance. The CODM allocates resources to and assesses the performance of each operating segment using information about the operating segment’s loss from operations.

 

Goodwill and Assets

 

   NanoVibronix   ENvue   Corporate   Total 
Balance sheet at March 31, 2026                    
Goodwill  $-   $29,082   $          -   $29,082 
Assets  $2,482   $37,389   $-   $39,871 
                     
Balance sheet at December 31, 2025                    
Goodwill  $-   $29,082   $-   $29,082 
Assets  $1,924   $39,200   $-   $41,124 

 

Segment operating results

 

Three Months Ended 31, 2026:  NanoVibronix   ENvue   Corporate   Total 
Revenues  $534   $119   $          -   $653 
Cost of revenues   389    319    -    708 
Research and development   40    428    -    468 
Selling and marketing   279    493    -    772 
General and administrative   380    643    1,393    2,416 
Impairment expense   -    -    -    - 
Total operating loss  $(554)  $(1,764)  $(1,393)  $(3,711)

 

Three Months Ended 31, 2025:  NanoVibronix   ENvue   Corporate   Total 
Revenues  $922   $103   $              -   $1,025 
Cost of revenues   590    66    -    656 
Research and development   412    118    -    530 
Selling and marketing   146    203    -    349 
General and administrative   386    157    799    1,342 
Total operating loss  $(612)  $(441)  $(799)  $(1,852)

 

 

ENVUE MEDICAL, INC.

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(Amounts in thousands except share and per share data)

 

Geographic Information and Major Customer Data

 

The following is a summary of revenues within geographic areas:

 

         
  

Three Months Ended

March 31

 
   2026   2025 
United States  $490   $986 
Europe   163    9 
Other   -    30 
Total  $653   $1,025 

 

Major Customer Data as a Percentage of Total Revenues

 

The following is a summary of revenues:

 

         
   Three Months Ended March 31, 
   2026   2025 
         
Customer A   27%   49%
Customer B   25%   1%
Customer C   14%   18%
Total   66%   68%